Reiner Laus, MD, is CEO and Co-Founder of TRIO Pharmaceuticals. Dr. Laus has been working on the development of cancer immunotherapies in an industrial setting for over 30 years. Dr. Laus was the founding CEO of Bolt Biotherapeutics, a publicly traded company that develops monoclonal antibodies for the treatment of cancer. Dr. Laus co-founded BN ImmunoTherapeutics (BNIT) as its CEO in 2005. BNIT was acquired by the publicly traded Danish vaccine developer Bavarian-Nordic and focused on the development of immunotherapies for cancer. Dr. Laus led the development of the company’s therapeutic for prostate cancer, PROSTVAC, to phase III development. Prior to this, Dr. Laus held the position of Vice President of R&D at Dendreon Corporation, where he worked for 11 years since Dendreon’s inception in 1993. During his tenure at Dendreon, Dr. Laus was instrumental in the discovery and development of PROVENGE, the first cancer vaccine to be approved by the FDA. Dr. Laus held academic appointments at the University of Kiel, Germany and at Stanford University, California.